Co-Occurrence of Helicobacter pylori and Candida spp. Infections in the Pathogenesis of Gastrointestinal Diseases

Biomedicines, Journal Year: 2025, Volume and Issue: 13(5), P. 1172 - 1172

Published: May 11, 2025

Helicobacter pylori and Candida spp. are widespread microorganisms found in the human gastrointestinal tract, often coexisting same ecological niche. H. pylori, a Gram-negative bacterium, is well-known pathogen responsible for gastritis, peptic ulcers, gastric cancer. In contrast, fungi, detected food, particularly albicans, generally considered commensal organisms, but can become opportunistic pathogens under certain conditions. Recent studies suggest possible link between these microorganisms, highlighting new survival strategy of that is, its ability to internalize vacuoles. This phenomenon, confirmed by various microscopic molecular techniques, may provide with protection against adverse environmental conditions, especially clinically important antibiotic therapy. The basic premise this theory penetrate vacuoles fungal cells, which then reservoir infection, allowing infection recur. Understanding interaction offer insights into pathogenesis diseases lead development treatments targeting both organisms simultaneously. purpose article review literature, considering first observations on problem literature current state knowledge, direction further research.

Language: Английский

The Potential of Cannabidiol in the Management of Oral Infections

Applied Sciences, Journal Year: 2025, Volume and Issue: 15(10), P. 5736 - 5736

Published: May 20, 2025

Oral infections, caused by bacterial, fungal, and viral pathogens, are a significant source of dental morbidity can lead to systemic complications, especially in immunocompromised individuals. Complex microbial interactions host immune responses drive common conditions such as caries, periodontal disease, oral candidiasis, herpetic lesions. Conventional antimicrobial therapies face limitations due resistance adverse effects, prompting interest alternative treatments. Cannabidiol (CBD), non-psychoactive compound derived from Cannabis sativa, has emerged promising candidate its antimicrobial, anti-inflammatory, immunomodulatory properties. CBD targets various molecular pathways, including cannabinoid receptors, TRP channels, adenosine PPARs, contributing multifaceted therapeutic effects. It demonstrated efficacy against pathogens Streptococcus mutans, Enterococcus faecalis, Candida albicans, disrupting biofilms bacterial membranes. Additionally, modulates inflammatory reducing cytokine production oxidative stress, particularly relevant chronic like disease. Emerging evidence also suggests synergistic effects with conventional antimicrobials benefits tissue regeneration. This review highlights the potential managing offering novel approach overcoming current treatment guiding future research into safer more effective health interventions.

Language: Английский